Despite current efficient treatments, the majority of HER2 positive, advanced invasive breast cancers treated with 1st line HER2 targeting therapy (trastuzumab and/or pertuzumab) together with chemotherapy are either initially non-responsive or develop resistant disease [1–3]. Here, ERBB2 is linked to invasive breast carcinoma.